IL152663A0 - Novel multicyclic compounds and the use thereof - Google Patents
Novel multicyclic compounds and the use thereofInfo
- Publication number
- IL152663A0 IL152663A0 IL15266301A IL15266301A IL152663A0 IL 152663 A0 IL152663 A0 IL 152663A0 IL 15266301 A IL15266301 A IL 15266301A IL 15266301 A IL15266301 A IL 15266301A IL 152663 A0 IL152663 A0 IL 152663A0
- Authority
- IL
- Israel
- Prior art keywords
- novel multicyclic
- multicyclic compounds
- compounds
- novel
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 abstract 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20294700P | 2000-05-09 | 2000-05-09 | |
| US09/850,858 US7122679B2 (en) | 2000-05-09 | 2001-05-08 | Multicyclic compounds and the use thereof |
| PCT/US2001/014996 WO2001085686A2 (en) | 2000-05-09 | 2001-05-09 | Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL152663A0 true IL152663A0 (en) | 2003-06-24 |
Family
ID=26898160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15266301A IL152663A0 (en) | 2000-05-09 | 2001-05-09 | Novel multicyclic compounds and the use thereof |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7122679B2 (cs) |
| EP (3) | EP1294725B1 (cs) |
| JP (1) | JP5156150B2 (cs) |
| KR (1) | KR100832602B1 (cs) |
| CN (2) | CN100554268C (cs) |
| AT (3) | ATE482215T1 (cs) |
| AU (1) | AU6132701A (cs) |
| BG (1) | BG66036B1 (cs) |
| BR (1) | BR0110993A (cs) |
| CA (1) | CA2409758A1 (cs) |
| CY (1) | CY1108722T1 (cs) |
| CZ (2) | CZ305350B6 (cs) |
| DE (3) | DE60116485T2 (cs) |
| DK (1) | DK1754707T3 (cs) |
| EA (1) | EA007868B1 (cs) |
| ES (2) | ES2315789T3 (cs) |
| HU (1) | HU229448B1 (cs) |
| IL (1) | IL152663A0 (cs) |
| MX (1) | MXPA02010977A (cs) |
| NO (1) | NO324256B1 (cs) |
| NZ (1) | NZ522539A (cs) |
| PL (1) | PL226805B1 (cs) |
| PT (1) | PT1754707E (cs) |
| SK (1) | SK287591B6 (cs) |
| UA (1) | UA73773C2 (cs) |
| WO (1) | WO2001085686A2 (cs) |
| ZA (1) | ZA200209065B (cs) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811992B1 (en) * | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US20060276497A1 (en) * | 2000-05-09 | 2006-12-07 | Cephalon, Inc. | Novel multicyclic compounds and the use thereof |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| JPWO2003051883A1 (ja) * | 2001-12-18 | 2005-04-28 | 協和醗酵工業株式会社 | インドール誘導体 |
| EP1501831A1 (en) * | 2002-04-26 | 2005-02-02 | Warner-Lambert Company Llc | Inhibitors of checkpoint kinases (wee1 and chk1) |
| US7094798B1 (en) | 2002-04-26 | 2006-08-22 | Pfizer Inc | Inhibitors of checkpoint kinases (Wee1 and Chk1) |
| WO2003093261A1 (en) | 2002-04-30 | 2003-11-13 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7511065B2 (en) | 2003-11-12 | 2009-03-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
| CN1905864B (zh) * | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| PT1684736E (pt) * | 2003-12-01 | 2011-11-10 | Cancer Res Inst | Inibidores de reparação de danos no adn para tratamento de cancro |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| CA2564952A1 (en) * | 2004-05-03 | 2005-11-24 | Janssen Pharmaceutica N.V. | Novel indole derivatives as selective androgen receptor modulators (sarms) |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| CA2595290C (en) | 2005-01-19 | 2013-06-25 | Mgi Gp, Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp |
| RU2447889C2 (ru) * | 2005-07-18 | 2012-04-20 | Бипар Сайенсиз, Инк. | Способ лечения рака (варианты) |
| CN102219741B (zh) * | 2005-09-02 | 2013-05-15 | 大塚制药株式会社 | 制备苯并氮杂*化合物或其盐的方法 |
| WO2007041357A1 (en) * | 2005-09-29 | 2007-04-12 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| AU2007292302A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing PARP inhibitors and uses thereof |
| EP2059498A4 (en) * | 2006-09-05 | 2011-01-12 | Bipar Sciences Inc | TREATMENT OF CANCER |
| EP2061479A4 (en) * | 2006-09-05 | 2010-08-04 | Bipar Sciences Inc | FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH |
| TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物 |
| WO2008063644A1 (en) * | 2006-11-20 | 2008-05-29 | Cephalon, Inc. | Method of radio-sensitizing tumors using a radio-sensitizing agent |
| US9061009B2 (en) * | 2007-06-08 | 2015-06-23 | University Of Massachusetts | Mixed lineage kinases and metabolic disorders |
| KR20100059950A (ko) | 2007-09-14 | 2010-06-04 | 아스트라제네카 아베 | 프탈라지논 유도체 |
| CN102083314B (zh) | 2007-10-03 | 2014-04-30 | 卫材股份有限公司 | Parp抑制剂化合物、组合物以及使用方法 |
| JP2011500684A (ja) * | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ，インコーポレイティド | ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物 |
| JP2011503111A (ja) * | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
| SG185954A1 (en) * | 2007-11-12 | 2012-12-28 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| AU2008333786A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| EP2250282A4 (en) * | 2008-02-04 | 2011-05-18 | Bipar Sciences Inc | METHOD FOR THE DIAGNOSIS AND TREATMENT OF PARP-MEDIATED DISEASES |
| JP2010006717A (ja) * | 2008-06-24 | 2010-01-14 | Kyorin Pharmaceut Co Ltd | ジヒドロチエノ［２，３−ｅ］インダゾール化合物 |
| KR101668499B1 (ko) | 2008-10-07 | 2016-10-21 | 아스트라제네카 유케이 리미티드 | 약학 제제 514 |
| WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
| EP2470540B1 (en) | 2009-08-26 | 2016-04-20 | Cephalon, Inc. | Novel forms of a multicyclic compound |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| WO2011077502A1 (ja) * | 2009-12-21 | 2011-06-30 | 杏林製薬株式会社 | ジヒドロチエノ［２，３－ｅ］インダゾール化合物 |
| US8999985B2 (en) | 2010-12-02 | 2015-04-07 | Shanghai De Novo Pharmatech Co Ltd. | Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof |
| US9771325B2 (en) | 2014-02-14 | 2017-09-26 | Council Of Scientific & Industrial Research | Tricyclic compounds and preparation thereof |
| WO2015121876A1 (en) * | 2014-02-14 | 2015-08-20 | Council Of Scientific & Industrial Research | Novel tricyclic compounds and preparation thereof |
| EP3224259A1 (en) | 2014-11-26 | 2017-10-04 | Cephalon, Inc. | Crystalline forms of parp inhibitors |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| EP3325623B3 (en) | 2015-07-23 | 2021-01-20 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| KR20190107656A (ko) | 2016-11-02 | 2019-09-20 | 이뮤노젠 아이엔씨 | 항체-약물 콘주게이트 및 parp 억제제로 병용 치료 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| AU2018260094A1 (en) | 2017-04-28 | 2019-11-07 | Akribes Biomedical Gmbh | A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| US20220305048A1 (en) | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
| CN110862396B (zh) * | 2019-11-29 | 2021-06-04 | 浙江工业大学 | 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法 |
| US20240270698A2 (en) | 2019-12-16 | 2024-08-15 | Korea Research Institute Of Chemical Technology | Novel pyrimidine derivative and use thereof |
| EP4079726A4 (en) | 2019-12-16 | 2024-01-24 | Korea Research Institute of Chemical Technology | Novel pyrimidin derivative and use thereof |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN113636970B (zh) * | 2021-09-13 | 2023-05-23 | 河北康泰药业有限公司 | 一种异吲哚酮的化合物、制备方法及其应用 |
| KR20230155351A (ko) | 2022-05-03 | 2023-11-10 | 한국화학연구원 | 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| KR20240156074A (ko) | 2023-04-21 | 2024-10-29 | (주)엠디바이오팜 | Hpk1 및 mlk3 저해제 및 이를 함유하는 항암용 조성물 |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
| KR20250041906A (ko) | 2023-09-19 | 2025-03-26 | (주)엠디바이오팜 | Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| DE3833008A1 (de) * | 1988-09-29 | 1990-04-05 | Goedecke Ag | Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| GB2239013B (en) * | 1989-11-01 | 1993-06-02 | Toyama Chemical Co Ltd | Novel isoindole derivatives and salts thereof,processes for producing the same and antitumor agent comprising the same |
| JP3025536B2 (ja) | 1990-12-27 | 2000-03-27 | 富山化学工業株式会社 | 新規なカルバゾール誘導体およびその塩 |
| JPH06507392A (ja) | 1991-02-26 | 1994-08-25 | エイアールシー １，インコーポレイテッド | 交感神経性の持続性疼痛の治療のための組成物および方法 |
| US5298506A (en) * | 1992-05-08 | 1994-03-29 | Brigham And Women's Hospital | Use of guanylate cyclase inhibitors in the treatment of shock |
| DE4217964A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
| GB9319297D0 (en) * | 1993-09-17 | 1993-11-03 | Wellcome Found | Indole derivatives |
| US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| AU1911095A (en) * | 1994-02-18 | 1995-09-04 | Cephalon, Inc. | Aqueous indolocarbazole solutions |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| ES2123873T3 (es) * | 1994-08-04 | 1999-01-16 | Hoffmann La Roche | Pirrolocarbazol. |
| US5705511A (en) | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| AU4889496A (en) | 1995-03-09 | 1996-10-02 | Kyowa Hakko Kogyo Co. Ltd. | Pyrrolocarbazole derivatives |
| WO1998007433A1 (en) * | 1996-08-22 | 1998-02-26 | Bristol-Myers Squibb Company | Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles |
| WO1998009967A1 (fr) | 1996-09-09 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Derives de pyrrolocarbazole |
| WO1999008680A1 (en) | 1997-08-15 | 1999-02-25 | The Johns Hopkins University | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
| WO1999011622A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| KR20010040939A (ko) | 1998-02-12 | 2001-05-15 | 몰레큐메틱스 리미티드 | β-시트 미메틱 및 이의 사용과 관련된 방법 |
| EP1070068B2 (en) | 1998-03-13 | 2007-01-17 | The University Of British Columbia | Granulatimide derivatives for use in cancer treatment |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| WO1999059973A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| WO1999065911A1 (en) | 1998-06-16 | 1999-12-23 | Ortho-Mcneil Pharmaceutical, Inc. | OCTAHYDROPYRROLO-[3,4-c]CARBAZOLES USEFUL AS ANALGESIC AGENTS |
| CA2339539A1 (en) * | 1998-08-26 | 2000-03-09 | Cephalon, Incorporated | Modulating multiple lineage kinase proteins |
| US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
-
2001
- 2001-05-08 US US09/850,858 patent/US7122679B2/en not_active Expired - Lifetime
- 2001-05-09 IL IL15266301A patent/IL152663A0/xx not_active IP Right Cessation
- 2001-05-09 PL PL363167A patent/PL226805B1/pl unknown
- 2001-05-09 CN CNB018120695A patent/CN100554268C/zh not_active Expired - Fee Related
- 2001-05-09 DE DE60116485T patent/DE60116485T2/de not_active Expired - Lifetime
- 2001-05-09 DE DE60143140T patent/DE60143140D1/de not_active Expired - Lifetime
- 2001-05-09 HU HU0302385A patent/HU229448B1/hu not_active IP Right Cessation
- 2001-05-09 PT PT05076862T patent/PT1754707E/pt unknown
- 2001-05-09 AT AT08075834T patent/ATE482215T1/de not_active IP Right Cessation
- 2001-05-09 SK SK1580-2002A patent/SK287591B6/sk not_active IP Right Cessation
- 2001-05-09 WO PCT/US2001/014996 patent/WO2001085686A2/en active Application Filing
- 2001-05-09 NZ NZ522539A patent/NZ522539A/en not_active IP Right Cessation
- 2001-05-09 CN CN2009101354977A patent/CN101560213B/zh not_active Expired - Fee Related
- 2001-05-09 ES ES05076862T patent/ES2315789T3/es not_active Expired - Lifetime
- 2001-05-09 MX MXPA02010977A patent/MXPA02010977A/es active IP Right Grant
- 2001-05-09 KR KR1020027015062A patent/KR100832602B1/ko not_active Expired - Fee Related
- 2001-05-09 DE DE60136305T patent/DE60136305D1/de not_active Expired - Lifetime
- 2001-05-09 JP JP2001582287A patent/JP5156150B2/ja not_active Expired - Fee Related
- 2001-05-09 ES ES01935215T patent/ES2256238T3/es not_active Expired - Lifetime
- 2001-05-09 DK DK05076862T patent/DK1754707T3/da active
- 2001-05-09 CZ CZ2011-756A patent/CZ305350B6/cs not_active IP Right Cessation
- 2001-05-09 CA CA002409758A patent/CA2409758A1/en not_active Abandoned
- 2001-05-09 AT AT05076862T patent/ATE411997T1/de active
- 2001-05-09 EA EA200201183A patent/EA007868B1/ru not_active IP Right Cessation
- 2001-05-09 AT AT01935215T patent/ATE315039T1/de active
- 2001-05-09 EP EP01935215A patent/EP1294725B1/en not_active Expired - Lifetime
- 2001-05-09 CZ CZ2002-3679A patent/CZ304911B6/cs not_active IP Right Cessation
- 2001-05-09 EP EP05076862A patent/EP1754707B1/en not_active Expired - Lifetime
- 2001-05-09 BR BR0110993-6A patent/BR0110993A/pt active Search and Examination
- 2001-05-09 EP EP08075834A patent/EP2050750B1/en not_active Expired - Lifetime
- 2001-05-09 AU AU6132701A patent/AU6132701A/xx active Pending
- 2001-09-05 UA UA2002129794A patent/UA73773C2/uk unknown
-
2002
- 2002-11-07 ZA ZA200209065A patent/ZA200209065B/en unknown
- 2002-11-08 NO NO20025376A patent/NO324256B1/no not_active IP Right Cessation
- 2002-12-05 BG BG107355A patent/BG66036B1/bg unknown
-
2009
- 2009-01-16 CY CY20091100056T patent/CY1108722T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6132701A (en) | Novel multicyclic compounds and the use thereof | |
| PT966447E (pt) | Moleculas pequenas uteis no tratamento de doencas inflamatorias | |
| WO2007149451A3 (en) | Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors | |
| MY135766A (en) | Quinolinones and naphthyridinones for treating inflammatory diseases | |
| WO2000038717A3 (en) | Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia | |
| MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
| WO2004093803A3 (en) | Photochemotherapeutic compounds for use in treatment of pin1-associated states | |
| ATE357272T1 (de) | Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten | |
| PL345560A1 (en) | Benzimidazole derivatives as modulators of ige | |
| WO2005016946A3 (en) | Platinum complexes for the treatment of tumors | |
| WO2003032916A3 (en) | Organosulfur inhibitors of tyrosine phosphatases | |
| NO20014560L (no) | Quinasoliner og terapautisk anvendelse derav | |
| ATE381935T1 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
| EE200300559A (et) | Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks | |
| NZ333232A (en) | Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease | |
| DE60016047D1 (de) | Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten | |
| TR200103125T2 (tr) | Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri. | |
| NO20005548L (no) | Mykobakterieinhibitorer | |
| ID30458A (id) | Osanetan dalam pengobatan gangguan jiwa | |
| EE200200670A (et) | S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks | |
| DE60133563D1 (de) | Külen | |
| TR200003084T2 (tr) | Paroxetine askorbat | |
| NO20030762D0 (no) | Forbedret spesifisitet i behandling av sykdommer | |
| UA64813C2 (uk) | Інтраназальний антисептик |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |